Ricardo Mestre-Pereira

Bellinzona, TI, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).

Journal: European urology oncology

Published: January 18, 2026

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Journal: Prostate cancer and prostatic diseases

Published: January 03, 2026

ChronoimmunoTOX: A Single-Institution Retrospective Study on How the Time of Administration Impacts Immune Checkpoint Inhibitor Efficacy and Toxicity in Melanoma.

ChronoimmunoTOX: A Single-Institution Retrospective Study on How the Time of Administration Impacts Immune Checkpoint Inhibitor Efficacy and Toxicity in Melanoma.

Journal: Journal of clinical medicine

Published: November 14, 2025

Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis.

Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis.

Journal: European urology oncology

Published: November 11, 2025

Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.

Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.

Journal: Cancers

Published: October 16, 2025

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Journal: Prostate cancer and prostatic diseases

Published: September 04, 2025

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Journal: Frontiers in oncology

Published: June 16, 2025

Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study.

Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study.

Journal: European urology open science

Published: October 31, 2024

Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis.

Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis.

Journal: European urology oncology

Published: February 26, 2024

Antiandrogens as Therapies for COVID-19: A Systematic Review.

Antiandrogens as Therapies for COVID-19: A Systematic Review.

Journal: Cancers

Published: October 29, 2023

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 08, 2023

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.

Journal: Therapeutic advances in medical oncology

Published: October 25, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026